Truvada® is indicated in combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
|NCPE Assessment Process||Ongoing|
|Rapid review received||12/06/2017|
|Rapid review completed||18/07/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Full pharmacoeconomic assessment commissioned by HSE||19/07/2017|
|Current Status||Awaiting applicant submission